ACADIA PHARMACEUTICALS INC. Stock Issued During Period, Value, Acquisitions
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, acquisitions for the quarter ending 2020-12-31 was $0.00.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, acquisitions for fiscal 2022 was $0.00.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, acquisitions for fiscal 2021 was $0.00, a 100.00% decline from fiscal 2020.
- ACADIA PHARMACEUTICALS INC. stock issued during period, value, acquisitions for fiscal 2020 was $44.28M.
| Period end | Stock Issued During Period, Value, Acquisitions 3 month | Stock Issued During Period, Value, Acquisitions 12 month |
|---|---|---|
| 2022-12-31 | $0.00 10-K · filed 2023-02-28 | |
| 2021-12-31 | $0.00 10-K · filed 2023-02-28 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $44.28M 10-K · filed 2023-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |